Skip to main navigation
×
CLOSE
Home
Development Programs
VX15 Immuno-Oncology
VX15 Neurology
VX18 Neurology
VX15 Autoimmune
NKT Vaccine
NKT Vaccine
ActivMAb
®
Vaccinia Display
Capabilities
Optimization
Target Identification
Publications
News & Publications
News
Publications
Careers
Corporate
Management
Partners
Contact
Investors
Main navigation
Investor Overview
News Releases
Events
Presentations
Stock Information
Stock Quote & Chart
Historical Price Lookup
Corporate Governance
Documents & Charters
Management
Board of Directors
Committee Composition
Financial Information
SEC Filings
Investor Services
Information Request
IR Contacts
E-mail Alerts
Events
Presentations
Home
About
Corporate Overview
Management
Partners
Pipeline
Pepinemab
Neurology
Pepinemab
Immuno-Oncology
Research & Development Programs
Clinical Trials
Patients
Physicians & Researchers
News & Publications
News
Publications
Investors
Main navigation
Investor Overview
News Releases
Events
Presentations
Stock Information
Stock Quote & Chart
Historical Price Lookup
Corporate Governance
Documents & Charters
Management
Board of Directors
Committee Composition
Financial Information
SEC Filings
Investor Services
Information Request
IR Contacts
E-mail Alerts
Events
Presentations
Careers
Contact Us
ActivMAb
®
Vaccinia
Antibody Discovery
Antigen Virus
Protein Optimization
Antigen Discovery
Antibody Optimization
ActivMAb
®
Contact
Science in the service of medicine
About
Corporate Overview
Management
Partners
Pipeline
Pepinemab Neurology
Pepinemab Immuno-Oncology
Research & Development Programs
Clinical Trials
Patients
Physicians & Researchers
News & Publications
News
Publications
Investors
Main navigation
Investor Overview
News Releases
Events
Presentations
Stock Information
Stock Quote & Chart
Historical Price Lookup
Corporate Governance
Documents & Charters
Management
Board of Directors
Committee Composition
Financial Information
SEC Filings
Investor Services
Information Request
IR Contacts
E-mail Alerts
Events
Presentations
Careers
Contact Us
ActivMAb
®
Vaccinia
Antibody Discovery
Antigen Virus
Protein Optimization
Antigen Discovery
Antibody Optimization
Contact Us
Investors
Investor Overview
News Releases
Events
Presentations
Stock Information
Corporate Governance
Financial Information
Investor Services
Shareholder Tools
Print Page
RSS Feeds
E-mail Alerts
IR Contacts
LinkedIn
Twitter
Filter by content type
(-)
News
(18)
Filter by form group
Filter by year
(-)
2021
(18)
Search
News
Vaccinex Announces Publication of Results from CLASSICAL-Lung Phase 1b/2 Clinical Trial in Non-Small Cell Lung Cancer in the Peer-Reviewed Journal Clinical Cancer Research
News
Vaccinex Reports First Quarter 2021 Financial Results and Provides Corporate Update
News
Vaccinex to Present at the Jefferies 2021 Virtual Healthcare Conference
News
Vaccinex Announces Activation of Clinical Sites to Enroll Patients in Studies of Pepinemab as Single Agent in Alzheimer’s Disease and in Combination with KEYTRUDA® in Advanced, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
News
Vaccinex to Chair Panel Q&A Session and Present Poster at the XV European Meeting on Glial Cells in Health and Disease
News
Vaccinex Reports Second Quarter 2021 Financial Results and Provides Corporate Update
News
Vaccinex CEO, Dr. Maurice Zauderer, Presented New and Promising Phase 2 SIGNAL Trial Data in a Plenary Session at the European Huntington’s Disease Network Meeting
News
Vaccinex to Present at the Oppenheimer & Co. Inc. Fall Healthcare Life Sciences and MedTech Summit
Pagination
Previous page
‹‹
Page 2